Clarity Pharmaceuticals (ASX:CU6) signed a commercial manufacturing agreement with SpectronRx for its diagnostic product, 64Cu-SAR-bisPSMA, according to a Tuesday filing with the Australian bourse.
SpectronRx's Indiana facility will offer on-demand commercial-scale manufacturing of copper-64 and 64Cu-SAR-bisPSMA, enabling distribution to all 50 states, the filing said.
The agreement allows for expansion into additional sites, increasing the manufacturing capacity of patient-ready doses of 64Cu-SAR-bisPSMA in US regional hubs, per the filing.
Shares rose 5% in midday trade on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.